Literature DB >> 29760223

Genomic Heterogeneity and the Small Renal Mass.

Daiki Ueno1, Zuoquan Xie1,2, Marta Boeke1, Jamil Syed1, Kevin A Nguyen1, Patrick McGillivray1, Adebowale Adeniran3, Peter Humphrey3, Garrett M Dancik4, Yuval Kluger3, Zongzhi Liu3, Harriet Kluger5, Brian Shuch6.   

Abstract

Purpose: Tumor heterogeneity may represent a barrier to preoperative genomic characterization by needle biopsy in clear cell renal cell carcinoma (ccRCC). The extent of heterogeneity in small renal tumors remains unknown. Therefore, we set out to evaluate heterogeneity in resected large and small renal tumors.Experimental Design: We conducted a study from 2013 to 2016 that evaluated 47 consecutive ccRCC tumors resected during radical or partial nephrectomy. Cases were designated as small (<4 cm) and large (>7 cm) tumors. Each tumor had three regions sampled. Copy-number variation (CNV) was assessed and gene expression analysis was performed to characterize the clear-cell A and B (ccA/ccB) profile and the cell-cycle progression (CCP) score. Genomic heterogeneity between three regions was evaluated using CNV subclonal events, regional expression profiles, and correlation between gene expression.
Results: Twenty-three small and 24 large tumors were analyzed. Total CNVs and subclonal CNVs events were less frequent in small tumors (P < 0.001). Significant gene expression heterogeneity was observed for both CCP scores and ccA/ccB classifications. Larger tumors had more variance in CCP scores (P = 0.026). The distribution of ccA/ccB differed between small and large tumors with mixed ccA/ccB tumors occurring more frequently in the larger tumors (P = 0.024). Analysis of five mixed tumors (with both ccA/ccB regions) demonstrated the more aggressive ccB phenotype had greater CNV events (P = 0.014).Conclusions: Small renal tumors have much less genomic complexity and fewer subclonal events. Pretreatment genomic characterization with single-needle biopsy in small tumors may be useful to assess biologic potential and may influence therapy. Clin Cancer Res; 24(17); 4137-44. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29760223      PMCID: PMC6125159          DOI: 10.1158/1078-0432.CCR-18-0214

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  26 in total

1.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

2.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.

Authors:  Samira A Brooks; A Rose Brannon; Joel S Parker; Jennifer C Fisher; Oishee Sen; Michael W Kattan; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; C Ryan Miller; Matthew E Nielsen; W Kimryn Rathmell
Journal:  Eur Urol       Date:  2014-02-25       Impact factor: 20.096

3.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

4.  Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

Authors:  Guillermo de Velasco; Aedín C Culhane; André P Fay; A Ari Hakimi; Martin H Voss; Nizar M Tannir; Pheroze Tamboli; Leonard J Appleman; Joaquim Bellmunt; W Kimryn Rathmell; Laurence Albiges; James J Hsieh; Daniel Y C Heng; Sabina Signoretti; Toni K Choueiri
Journal:  Oncologist       Date:  2017-02-20

5.  Grade heterogeneity in small renal masses: potential implications for renal mass biopsy.

Authors:  Mark W Ball; Stephania M Bezerra; Michael A Gorin; Morgan Cowan; Christian P Pavlovich; Phillip M Pierorazio; George J Netto; Mohamad E Allaf
Journal:  J Urol       Date:  2014-06-21       Impact factor: 7.450

6.  Renal cell cancer stage migration: analysis of the National Cancer Data Base.

Authors:  Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

7.  A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.

Authors:  Todd M Morgan; Rohit Mehra; Placede Tiemeny; J Stuart Wolf; Shulin Wu; Zaina Sangale; Michael Brawer; Steven Stone; Chin-Lee Wu; Adam S Feldman
Journal:  Eur Urol       Date:  2017-12-14       Impact factor: 20.096

8.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

9.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.

Authors:  Marco Gerlinger; Stuart Horswell; James Larkin; Andrew J Rowan; Max P Salm; Ignacio Varela; Rosalie Fisher; Nicholas McGranahan; Nicholas Matthews; Claudio R Santos; Pierre Martinez; Benjamin Phillimore; Sharmin Begum; Adam Rabinowitz; Bradley Spencer-Dene; Sakshi Gulati; Paul A Bates; Gordon Stamp; Lisa Pickering; Martin Gore; David L Nicol; Steven Hazell; P Andrew Futreal; Aengus Stewart; Charles Swanton
Journal:  Nat Genet       Date:  2014-02-02       Impact factor: 38.330

10.  Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes.

Authors:  Garrett M Dancik; Dan Theodorescu
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

View more
  3 in total

Review 1.  Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management.

Authors:  Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi
Journal:  Eur Urol Focus       Date:  2019-04-28

2.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.

Authors:  Johannes C van der Mijn; Bashir Al Hussein Al Awamlh; Aleem Islam Khan; Lina Posada-Calderon; Clara Oromendia; Jonathan Fainberg; Mark Alshak; Rahmi Elahjji; Hudson Pierce; Benjamin Taylor; Lorraine J Gudas; David M Nanus; Ana M Molina; Joseph Del Pizzo; Douglas S Scherr
Journal:  PLoS One       Date:  2019-12-09       Impact factor: 3.240

3.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.

Authors:  Johannes C van der Mijn; Kenneth W Eng; Pooja Chandra; Evan Fernandez; Sinan Ramazanoglu; Alexandros Sigaras; Clara Oromendia; Lorraine J Gudas; Scott T Tagawa; David M Nanus; Bishoy F Faltas; Himisha Beltran; Cora N Sternberg; Olivier Elemento; Andrea Sboner; Juan Miguel Mosquera; Ana M Molina
Journal:  Mol Oncol       Date:  2022-04-05       Impact factor: 7.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.